YUMAB

    OverviewSuggest Edit

    YUMAB is a company that specializes in contract research, technologies, and R&D services for the development of antibodies. It builds a platform with human antibody libraries that provides in vitro selection technologies including on-cells-selection for difficult targets. In addition, the platform offers a comprehensive portfolio of antibody engineering and humanization technologies.
    TypePrivate
    Founded2012
    HQBraunschweig, DE
    Websiteyumab.com

    Latest Updates

    Employees (est.) (Sept 2021)18(-5%)
    Cybersecurity ratingAMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at YUMAB

    Thomas Schirrmann

    Thomas Schirrmann

    CEO
    André Frenzel

    André Frenzel

    Founder & CSO
    Stefan Dübel

    Stefan Dübel

    Board Member
    Michael Hust

    Michael Hust

    Founder
    Alexander Ehm

    Alexander Ehm

    Head of Global Business Development
    Show more

    YUMAB Office Locations

    YUMAB has offices in Braunschweig and Atlanta
    Braunschweig, DE (HQ)
    Inhoffenstraße 7
    Atlanta, GA, US
    1100 South Tower, 225 Peachtree St NE
    Show all (2)

    YUMAB Financials and Metrics

    Summary Metrics

    Founding Date

    2012

    YUMAB Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    90/100

    SecurityScorecard logo

    YUMAB Online and Social Media Presence

    Embed Graph

    YUMAB Blogs

    First hospitalized COVID-19 patient treated with COR-101 antibody

    Der Beitrag First hospitalized COVID-19 patient treated with COR-101 antibody erschien zuerst auf YUMAB GmbH.

    Human SARS-CoV-2 antibody COR-101 shows high efficacy in animal model

    Der Beitrag Human SARS-CoV-2 antibody COR-101 shows high efficacy in animal model erschien zuerst auf YUMAB GmbH.

    Mechanism of action for human SARS-CoV-2 antibody COR-101 identified

    Der Beitrag Mechanism of action for human SARS-CoV-2 antibody COR-101 identified erschien zuerst auf YUMAB GmbH.

    CORAT’s human COVID-19 antibody ready for clinical trials

    Der Beitrag CORAT’s human COVID-19 antibody ready for clinical trials erschien zuerst auf YUMAB GmbH.

    Innovation Award for CORAT’s COVID-19 antibody development

    Der Beitrag Innovation Award for CORAT’s COVID-19 antibody development erschien zuerst auf YUMAB GmbH.

    YUMAB Frequently Asked Questions

    • When was YUMAB founded?

      YUMAB was founded in 2012.

    • Who are YUMAB key executives?

      YUMAB's key executives are Thomas Schirrmann, André Frenzel and Stefan Dübel.

    • How many employees does YUMAB have?

      YUMAB has 18 employees.

    • Who are YUMAB competitors?

      Competitors of YUMAB include Protein Technologies, PharmaBio and Spiderwort.

    • Where is YUMAB headquarters?

      YUMAB headquarters is located at Inhoffenstraße 7, Braunschweig.

    • Where are YUMAB offices?

      YUMAB has offices in Braunschweig and Atlanta.

    • How many offices does YUMAB have?

      YUMAB has 2 offices.